Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Leading Inpatient Medical Detox Provider Launches Expansion of Benzodiazepine Taper Program

The Gallus Benzodiazepine Taper Program expands to include virtual patient support; addresses the rise in benzodiazepine prescribing crisis that has risen to alarming rates


News provided by

Gallus Medical Detox Centers

Mar 25, 2021, 10:00 ET

Share this article

Share toX

Share this article

Share toX


DENVER, Mar. 25, 2021 /PRNewswire-PRWeb/ -- Gallus Medical Detox Centers (Gallus), an inpatient drug and alcohol medical detox services provider, announces today the expansion of the Gallus Benzodiazepine Taper Program. An extension of inpatient detoxification services, the taper program expands patient recovery support to include virtual patient services, such as telehealth visits for medication management and telehealth therapy sessions, that coordinate with aftercare providers to facilitate recovery.

Benzodiazepines are highly addictive sedative drugs that are often prescribed to treat a range of conditions, including panic and anxiety disorders, seizures and insomnia. The more familiar names include Ativan, Valium and Xanax, and the prescriptions of these addicted substances have risen at alarming rates. According to the American Journal of Public Health, between 1996 and 2013, the number of adults filling a benzodiazepine prescription increased 67 percent, from 8.1 million to 13.5 million (1). Additionally, a report in Psychiatric Services found that in 2018, nearly 13% of adults in the United States reported abusing benzodiazepines, with misuse accounting for roughly 18% of overall use (2). And this isn't something that only affects young adults. Long term use of benzodiazepines, which can lead to dependence, addiction and cognitive damage, occurs in almost 32% of adults between the ages of 65 and 80 (3).

The benzodiazepine crisis has unfortunately been overshadowed...just because we’re not talking about it doesn’t mean it isn’t happening.

Post this

"The benzodiazepine crisis has unfortunately been overshadowed by other drug epidemics, including opioids, and more recently the COVID-19 pandemic. Just because we're not talking about it doesn't mean it isn't happening and that many people aren't suffering from severe and even life-threating addictions," says Patrick Gallus, D.O., Founder and Chief Medical Officer of Gallus Medical Detox Centers. "Even more alarming is that many patients are unaware of their addictive properties and how dangerous they can be when combined with other prescription and non-prescription drugs, as well as alcohol. By expanding the Gallus Benzodiazepine Taper Program to include virtual services, we will reach more patients who are struggling with an addiction and are seeking a road to lasting recovery."

Because benzodiazepine's have a long half-life, it can be physically and psychologically taxing to go through withdrawal. Therefore, a tapering program helps the patient start their recovery journey by slowly decreasing their consumption of the substance, allowing them to fully focus on the withdrawal and enter into a long-term rehabilitation facility sober. The Gallus Benzodiazepine Taper Program, which can last from three weeks to six months, involves both medical and therapy visits. In addition to a personalized treatment plan, each patient's recovery plan includes aftercare planning which identifies resources and next steps toward long-term recovery.

Because benzodiazepines alter the brain's chemistry in a way that can impact cognitive, behavioral and emotional, and cardiovascular functions, abruptly ceasing long-term benzodiazepine use can cause too dramatic a change in brain activity, leading to unpleasant side effects including, intense anxiety, convulsions and seizures and muscle/joint pain, among others. In some cases, benzodiazepine withdrawal can also be life-threating. For these reasons and more, it is essential that patients who are looking to begin their path to recovery do so under the medical expertise, care and guidance of a medical detox inpatient facility.

"The physical ramifications of benzodiazepine misuse and addiction are severe but the psychological impact can actually be more damaging on the exact thing that it is intended to treat, like anxiety. Research is clear that long term consistent benzodiazepine use worsens anxiety and panic over time," says Steve Carleton LCSW, CACIII, Clinical Director at Gallus Medical Detox Centers. "The Gallus Benzodiazepine Taper Program not only improves access to quality and compassionate care that puts the comfort and dignity of the patient first, but it increases the success of recovery by incorporating psychotherapy into the beginning of a patient's recovery journey."

Gallus has been offering tapering programs since 2016 and in an effort to reach more patients, is expanding to use virtual technology. In addition to treating benzodiazepine addiction, Gallus provides medical detox services for substance use disorders, including alcohol, opioid, stimulants, polysubstance and others. It also has the expertise to treat patients with acute substance use disorders and co-occurring mental health or chronic physical conditions. Services are offered through the Gallus Method, a proprietary method that uses expertly trained medical teams to administer evidence-based IV medication protocols to deliver a world class patient experience.

The Gallus Benzodiazepine Taper Program is currently accepting patients at its locations in Scottsdale, Arizona and Littleton, Colorado. For those who are seeking professional help to treat a benzodiazepine addiction, please visit gallusdetox.com or call 888-306-3122 for Admissions.

1 Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013 | AJPH | Vol. 106 Issue 4 (aphapublications.org)

2 Benzodiazepine Use and Misuse Among Adults in the United States | Psychiatric Services (psychiatryonline.org)

3 Despite risks, benzodiazepine use highest in older people | National Institutes of Health (NIH)

About Gallus Medical Detox Centers
Gallus Medical Detox Centers provide the highest quality inpatient medical detox services using evidence-based IV medication protocols that avoid cross-addiction, delivered by highly trained medical staff, in a safe, comfortable and private patient environment that optimizes treatment outcomes.
With locations in Arizona and Colorado, Gallus' vision is to be the best, first step in overcoming substance use disorders for patients needing medical detox and to lead the field in the science, education, training and customer experience. Through the Gallus Method, patients receive unique, personalized and 24-hour care delivered in a professional, safe and peaceful environment to achieve an optimal physiological withdrawal experience that will move them into behavioral health therapy and ultimately find long-term recovery.

# # #
Media Contact:
Gallus Media Relations
[email protected]
239-297-6592

Media Contact

Gallus Communications, Gallus Medical Detox Centers, +1 (239) 297-6592, [email protected]

SOURCE Gallus Medical Detox Centers

Related Links

https://www.gallusdetox.com/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.